{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:05:31Z","timestamp":1791295531249,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":5227,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> For 366 patients with polycythaemia vera (PV) or essential thrombocythaemia (ET) diagnosed 1971\u20131990, oral administration of 32\u2010P was used as myelosuppressive treatment. Retreatment was not restricted to any defined interval and the number of treatments or the total dose were not limited. For 107 patients, follow\u2010up was &gt; 10 years. 15 of these presented with life\u2010threatening occlusive vascular symptoms and their survival was short. For the remaining 92 patients 5\u2010yr survival was not significantly worse than for a Swedish population matched for age and sex. Survival at 10 yr was lower, 51% versus 66% expected. Acute myeloid leukaemia (AML) was diagnosed in 11 of the 107 patients (10.3%). In the whole material of 366 patients, 17 have developed AML with a median time of 8.5 yr from start of treatment. There was a maximum incidence of 4% per yr after 8\u201312 yr. Later, the incidence decreased. The median annual dose of 32\u2010P for the AML patients was 100 MBq and was not significantly larger than for a matched control group surviving without AML, 96 MBq. The results are compared with reports on PV or ET patients treated with busulphan (Bu) or hydroxyurea (HU). With comparable periods of follow\u2010up there are no indications that an adequate myelosuppression with oral 32\u2010P will be associated with shorter survival or higher incidence of AML than treatment with Bu or HU. It is concluded that, for the time being, oral administration of 32\u2010P is an acceptable standard treatment in PV and ET.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1995.tb01621.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T12:40:45Z","timestamp":1279456845000},"page":"21-26","source":"Crossref","is-referenced-by-count":45,"title":["Survival and risk of leukaemia in polycythaemia vera and essential thrombocythaemia treated with oral radiophosphorus: Are safer drugs available?"],"prefix":"10.1111","volume":"54","author":[{"given":"L.","family":"Brandt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1962.tb07186.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198102193040801"},{"key":"e_1_2_1_4_2","first-page":"156","article-title":"Acute leukemia in polycythemia vera","volume":"23","author":"Landaw SA.","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1981.150"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1985.tb02880.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1984.2.6.558"},{"key":"e_1_2_1_8_2","first-page":"167","article-title":"Long\u2010term management of polycythemia vera with hydroxyurea","volume":"23","author":"Kaplan ME","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00212.x"},{"key":"e_1_2_1_10_2","first-page":"177","article-title":"Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy S","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880615)61:12<2487::AID-CNCR2820611217>3.0.CO;2-T"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-468X(85)90011-X"},{"key":"e_1_2_1_14_2","volume-title":"Statistical methods in cancer research","author":"Breslow NE","year":"1980"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880101)61:1<89::AID-CNCR2820610115>3.0.CO;2-0"},{"key":"e_1_2_1_16_2","first-page":"1951","article-title":"Traitement des polyglobulies par 32P avec ou sans traitement d'entretien par hydroxyur\u00e9e","volume":"22","author":"Najean Y","year":"1993","journal-title":"Press Med"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1994.tb01303.x"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(90)90164-6"},{"key":"e_1_2_1_19_2","first-page":"606","article-title":"Chronic myelomonocytic leukemia transformation in polycythemia vera","volume":"5","author":"Holcombe RF","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_1_20_2","first-page":"33","article-title":"Acute leukemia in polycythemia vera","volume":"13","author":"Landaw SA.","year":"1976","journal-title":"Semin Hematol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198703000-00012"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1995.tb01621.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1995.tb01621.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:20:52Z","timestamp":1698366052000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1995.tb01621.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1111\/j.1600-0609.1995.tb01621.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1995.tb01621.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}